Anaphylaxis Treatment Market to Grow at a CAGR of 8.7% to reach US$ 4,787.66 million from 2021 to 2028

The anaphylaxis treatment market is expected to reach US$ 4,787.66 million in 2028 from US$ 2,664.66 million in 2021; it is estimated to grow at a CAGR of 8.7% during 2021–2028.

Anaphylaxis is an allergic reaction that can further lead to a fatal condition known as anaphylactic shock. Anaphylaxis occurs when the patient's body reacts to a foreign substance and produces a high amount of histamine that triggers an inflammatory response. As per the Asthma and Allergy Foundation of America (AAFA), in the US, every year, there are around 200,000 hospital visits due to food allergies. The growth of the anaphylaxis treatment market is attributed to the factors such as rising incidence of anaphylaxis, and recent approvals of epinephrine. However, poor accessibility to epinephrine auto-injectors in low-income countries hinders the market growth.  

Lucrative Regions for Anaphylaxis Treatment Market

Get more information on this report : Request Free Sample PDF

Market Insights

Rising Incidence of Anaphylaxis

Anaphylaxis is a severe, life‑threatening allergic reaction caused by vulnerability to allergens (foods, insect stings, or medicines) identified as a non-self by a human body. Typical indications of this condition include swallowing and breathing difficulties, skin redness and itching, accelerated heart rate, wheezing, rapid breathing rate, and lowering blood pressure. The incidence of anaphylaxis is increasing around the world. According to the National Institute for Health and Care Excellence (NICE), anaphylaxis causes more than 20 deaths every year in the UK. As per the European Academy of Allergy and Clinical Immunology data, ~150 million Europeans suffer from chronic allergic diseases every year. Therefore, the rising incidence of allergies is leading to surge in anaphylaxis cases. Moreover, as per the Allergy Facts by the American College of Allergy, Asthma & Immunology, more than 50 million people experience different types of allergies every year.

1–15% of the US population is at the risk of having an anaphylactic reaction when exposed to one or more allergens, and up to 1% of these patients die due to anaphylaxis. The condition results in ~1,500 deaths per year in the US; also list allergies as the sixth-leading circumstance of chronic illness. Moreover, as per the Asthma and Allergy Foundation of America (AAFA), due to increasing food allergic reactions, the number of hospital visits has increased. Food allergies are the cause of more than 200,000 emergency room (ER) visits annually. Food Allergy Research & Education states that more than 32 million Americans live with life-threatening food allergies. Due to the growing prevalence of allergies, the economic burden on healthcare systems in many countries is increasing. For instance, according to Allergy Facts, the annual cost of managing the cases of allergies is more than US$ 18 billion in the US. Thus, the burgeoning incidence of anaphylaxis is driving the growth of the market.

Medication Type -Based Insights

Based on medication type, the anaphylaxis treatment market is segmented into epinephrine, antihistamines, steroids, beta-agonist, and others. The epinephrine segment held the largest share of the market in 2020 and is anticipated to register the highest CAGR in the market during the forecast period.

Anaphylaxis Treatment Market, by Medication Type– 2020 and 2028

Get more information on this report : Request Free Sample PDF

Route of Administration -Based Insights

Based on route of administration, the anaphylaxis treatment market is segmented into oral, parenteral, and others. The parenteral segment held the largest share of the market in 2020, whereas the oral segment is anticipated to register the highest CAGR of 8.9% in the market during the forecast period.

Allergy Type-based Insights

Based on allergy type, the anaphylaxis treatment market is segmented into food allergy, medications, insect stings, and others. The food allergy segment held the largest share of the market in 2020 and is estimated to register the highest CAGR in the market during the forecast period.

Distribution Channel-based Insights

Based on distribution channel, the anaphylaxis treatment market is segmented into hospital pharmacies, retail sales, drug store mail, and others. The retail sales segment held the largest share of the market in 2020 and is estimated to register the highest CAGR in the market during the forecast period.

Strategic Insights

Product launches and approvals are the commonly adopted strategies by companies to expand their global footprints and product portfolios. Moreover, the anaphylaxis treatment market players focus on the collaboration strategy to enlarge their clientele, which, in turn, permits them to maintain their brand name globally.

Anaphylaxis Treatment Market – by Medication Type

• Epinephrine
• Antihistamines
• Steroids
• Beta-Agonist
• Others

Anaphylaxis Treatment Market – by Route of Administration

• Oral
• Parenteral
• Others

Anaphylaxis Treatment Market – by Allergy Type

• Food Allergy
• Medications
• Insect Stings
• Others

Anaphylaxis Treatment Market – by Distribution Channel

• Hospital Pharmacies
• Retail Sales
• Others

Anaphylaxis Treatment Market – by Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • France
  • Germany
  • Italy
  • UK
  • Spain
  • Rest of Europe
• Asia Pacific (APAC)
  • China
  • India
  • South Korea
  • Japan
  • Australia
  • Rest of Asia Pacific
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
• South and Central America (SCAM)
  • Brazil
  • Argentina
  • Rest of South and Central America

Company Profiles

• Amneal Pharmaceuticals Inc.
• Bioprojet
• Mylan N.V.
• Adamis Pharmaceutical Corporation
• Abbott
• Pfizer Inc.
• Glaxosmithkline Plc.
• Merck And Co., Inc.
• Teva Pharmaceutical Industries Ltd.  
• ALK-ABELLó